TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10418540

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 50 mg (cycle 1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 100 mg (cycle 2)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 7743984

Group type: COMPARATOR
Intervention: Cycling (CYC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Running (RUN)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-fat/low-carbohydrate foods (after CYC or RUN)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-fat/high-carbohydrate foods (after CYC or RUN)
Number of subjects: 24
Study: 2153765

Group type: EXPERIMENTAL
Intervention: CAV-HEM chemotherapy
Number of subjects: 577

Group type: COMPARATOR
Intervention: CAV chemotherapy
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: CAV maintenance therapy
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: CAV-HEM with no maintenance therapy
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 577
Study: 7387765

Group type: EXPERIMENTAL
Intervention: CEX (cephalexin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CCL (cefaclor)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CDX (cefadroxil)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CEX (cephalexin) during breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CDX (cefadroxil) during breakfast
Number of subjects: 12
Study: 31851833

Group type: EXPERIMENTAL
Intervention: Instagram abstention for one week (intervention group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Instagram usage (control group)
Number of subjects: 80
Study: 28737452

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program (1-hour sessions weekly for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group (relaxation techniques weekly)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 27077277

Group type: EXPERIMENTAL
Intervention: IVR‐T reminder at index clinic (IC)
Number of subjects: 8804

Group type: EXPERIMENTAL
Intervention: IVR‐T reminder at replication clinic (RC)
Number of subjects: 8804

Group type: COMPARATOR
Intervention: No reminder at index clinic (IC)
Number of subjects: 8804

Group type: COMPARATOR
Intervention: No reminder at replication clinic (RC)
Number of subjects: 8804

Group type: EXPERIMENTAL
Intervention: Prediction model for missed appointments
Number of subjects: 8804
Study: 25015615

Group type: COMPARATOR
Intervention: Single dose (0.4 mg tamsulosin)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Double dose (0.4 mg tamsulosin + 10 mg alfuzosin)
Number of subjects: 70
Study: 22441634

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200μg once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 50
Study: 20423436

Group type: EXPERIMENTAL
Intervention: Oral education
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 63
Study: 18671885

Group type: EXPERIMENTAL
Intervention: Oxpentifylline (400 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (1 tablet daily)
Number of subjects: 0
Study: 15954959

Group type: EXPERIMENTAL
Intervention: PEEP (5 cmH(2)O)
Number of subjects: 20

Group type: COMPARATOR
Intervention: ZPEEP (no PEEP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline values in CVP and MAP
Number of subjects: 20
Study: 19753737

Group type: EXPERIMENTAL
Intervention: Dexpanthenol-containing cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 0
Study: 10333183

Group type: EXPERIMENTAL
Intervention: Low Vision Functional Status Evaluation (LVFSE)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Self-reported task performance difficulty
Number of subjects: 155
Study: 8529437

Group type: EXPERIMENTAL
Intervention: Once-a-day isepamicin combined with piperacillin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Twice-a-day combined administration
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional regimen
Number of subjects: 34
Study: 2028709

Group type: EXPERIMENTAL
Intervention: Cytidine 5'-diphosphocholine (2 g iv infusion)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cytidine 5'-diphosphocholine + GHRH
Number of subjects: 11

Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 11
Study: 6987042

Group type: EXPERIMENTAL
Intervention: Cephradine given twice daily (70 patients)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Cephradine given four times daily (61 patients)
Number of subjects: 131
Study: 30299258

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 28661773

Group type: EXPERIMENTAL
Intervention: Resisted sprint swim training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonresisted sprint swim training
Number of subjects: 24
Study: 27883295

Group type: EXPERIMENTAL
Intervention: ABCB11 rs7602171G>A
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: GSTP1 rs1799811C>T
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SLC5A6 rs1395
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ABCB4 rs2302387C>T
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ABCC5 rs939339A>G
Number of subjects: 74
Study: 25125580

Group type: EXPERIMENTAL
Intervention: PF‐05105679 (600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐05105679 (900 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone (20 mg)
Number of subjects: 0
Study: 23137206

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study: 20711603

Group type: EXPERIMENTAL
Intervention: Training group at neck resting position (NRT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Training group at 20° neck flexion position (NFT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 30
Study: 18928997

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin C 1000 mg and vitamin E 400 IU)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study: 15834703

Group type: EXPERIMENTAL
Intervention: Immune-enhancing (IE) enteral nutrition
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-immune-enhancing (NIE) enteral nutrition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (IE and NIE)
Number of subjects: 38
Study: 12510551

Group type: EXPERIMENTAL
Intervention: Cranial arm positioning (n = 31)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Caudal arm positioning (n = 55)
Number of subjects: 86
Study: 9822137

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 470

Group type: COMPARATOR
Intervention: Nisoldipine
Number of subjects: 470
Study: 7854804

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study: 2491361

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg once daily
Number of subjects: 257

Group type: COMPARATOR
Intervention: Cimetidine, 800 mg once daily
Number of subjects: 257
Study: 1093984

Group type: EXPERIMENTAL
Intervention: Desoximetasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betamethasone valerate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 0
Study: 31675553

Group type: EXPERIMENTAL
Intervention: Auditory cognitive task presented during the first 8 minutes of Adaptation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Auditory cognitive task presented during the last 8 minutes of Adaptation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive task presented during the entire split‐belt Adaptation phase (14 minutes)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive task presented during four 2-minute bouts (8 minutes)
Number of subjects: 40
Study: 31621819

Group type: EXPERIMENTAL
Intervention: Face images with both surface reflectance and shape information present (reflectance and shape version)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Face images with shape information removed but surface reflectance present (reflectance version)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Face images with surface reflectance information removed but shape present (shape version)
Number of subjects: 195
Study: 28221056

Group type: EXPERIMENTAL
Intervention: CT + Memory Support (n = 25)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CT-as-usual (n = 23)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CT + Memory Support
Number of subjects: 48
Study: 25505238

Group type: EXPERIMENTAL
Intervention: Screening at ages 55 to 59 years with two-year intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening at short intervals of three years or less
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening above age 63 years
Number of subjects: 0
Study: 23895087

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 79
Study: 21550950

Group type: EXPERIMENTAL
Intervention: Insulin detemir at 50% of intravenous basal insulin requirements
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Insulin detemir at 65% of intravenous basal insulin requirements
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Insulin detemir at 80% of intravenous basal insulin requirements
Number of subjects: 82
Study: 18807247

Group type: EXPERIMENTAL
Intervention: Delta(9)‐THC (0.0286 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17114166

Group type: EXPERIMENTAL
Intervention: Keyboard access (active learning)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mouse access (passive learning)
Number of subjects: 30
Study: 14756616

Group type: EXPERIMENTAL
Intervention: Naturalistic sample of pathological gamblers who had recently quit gambling
Number of subjects: 101
Study: 11298545

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (ALA-PDT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 88
Study: 9539890

Group type: EXPERIMENTAL
Intervention: Blinded assessment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unblinded assessment
Number of subjects: 20
Study: 8290236

Group type: EXPERIMENTAL
Intervention: Neopanpur (EGIS) 3 x 2 for 10 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Creon (Kalichemie) 10,000 3 x 2 for 10 days
Number of subjects: 15
Study: 2657499

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cinoxacin
Number of subjects: 40
Study: 30336808

Group type: EXPERIMENTAL
Intervention: Oral administration of granisetron (1 mg tablet, twice daily every 12 hours for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal delivery of granisetron (34.3 mg/52 cm2 patch for 6 days)
Number of subjects: 0
Study: 31933068

Group type: EXPERIMENTAL
Intervention: Serum DSA-TRF
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Serum TRF
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: GlycoTRF1
Number of subjects: 581
Study: 31589634

Group type: EXPERIMENTAL
Intervention: Spanish version of the Job Crafting Questionnaire (JCQ)
Number of subjects: 768
Study: 28558627

Group type: EXPERIMENTAL
Intervention: Exposure to a news clip about an Iranian nuclear attack on Israel
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no exposure to the film)
Number of subjects: 154
Study: 27127999

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23231573

Group type: EXPERIMENTAL
Intervention: Complete abstinence
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Conditional abstinence
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Controlled drinking
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Combined behavioral intervention
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 1226
Study: 21660397

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (zinc acetate syrup)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (vitamin B-complex syrup)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 18377135

Group type: EXPERIMENTAL
Intervention: Counterargument appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivating action appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dissonance appeal
Number of subjects: 0
Study: 17213598

Group type: EXPERIMENTAL
Intervention: Group A: 7.5 mg bupivacaine + 5 microg sufentanil + 10% glucose
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group B: 7.5 mg bupivacaine + 7.5 microg sufentanil + 10% glucose
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C: 15 mg bupivacaine + 10% glucose
Number of subjects: 90
Study: 11818299

Group type: EXPERIMENTAL
Intervention: Antidrug public service announcements (PSAs)
Number of subjects: 3608

Group type: COMPARATOR
Intervention: Control condition (non-drug-related television program)
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: Antidrug PSAs
Number of subjects: 3608
Study: 10430716

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm delivered during inspiration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (16 micrograms/kg/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Norepinephrine (to obtain a 3 mm Hg rise in mean pulmonary arterial pressure)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Norepinephrine + Inhaled NO
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate + Inhaled NO
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate + Norepinephrine + Inhaled NO
Number of subjects: 16
Study: 7548461

Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dim light therapy
Number of subjects: 27
Study: 2144835

Group type: EXPERIMENTAL
Intervention: Nicotinamide (100 mg/year of age up to a maximum of 1.5 g/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 35
Study: 6996121

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone‐releasing hormone (LH‐RH) 500 micrograms 8‐hourly
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 6361311

Group type: EXPERIMENTAL
Intervention: Cefadroxil granules (CDX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-acting cephalexin granules (L-CEX)
Number of subjects: 0
Study: 30286416

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 45 minutes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 29329498

Group type: EXPERIMENTAL
Intervention: Lithium (n=11)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Quetiapine (n=21)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Psychotic subgroup (n=32)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Non-psychotic subgroup
Number of subjects: 303
Study: 27431306

Group type: EXPERIMENTAL
Intervention: Daily nasal saline irrigation supported by a demonstration video
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Daily steam inhalation
Number of subjects: 871

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Combined treatment with both interventions
Number of subjects: 871
Study: 25080906

Group type: EXPERIMENTAL
Intervention: Zero-balanced ultrafiltration with modified ultrafiltration (Z+M group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zero-balanced ultrafiltration (Z group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified ultrafiltration (M group)
Number of subjects: 60
Study: 22040532

Group type: EXPERIMENTAL
Intervention: SABA purchased with prescription
Number of subjects: 316

Group type: COMPARATOR
Intervention: SABA purchased without prescription
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Anti‐inflammatory asthma medication
Number of subjects: 316
Study: 20307568

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical tests (FIT)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Guaiac-based fecal occult blood tests (gFOBT)
Number of subjects: 404
Study: 17508621

Group type: EXPERIMENTAL
Intervention: Photodisinfection (PD) alone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP) alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SRP combined with Photodisinfection (SRP + PD)
Number of subjects: 33
Study: 16285996

Group type: EXPERIMENTAL
Intervention: Triflusal 300 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triflusal 600 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triflusal 900 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aspirin 100 mg/day
Number of subjects: 60
Study: 12064848

Group type: EXPERIMENTAL
Intervention: Strength training (FMT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (FMC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 21
Study: 10414671

Group type: EXPERIMENTAL
Intervention: Clonidine (3‐4 mcg/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7587754

Group type: EXPERIMENTAL
Intervention: Transurethral resection (TUR)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 249
Study: 2107013

Group type: EXPERIMENTAL
Intervention: terfenadine started before symptoms
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: terfenadine started after symptoms
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 6776161

Group type: EXPERIMENTAL
Intervention: 100 mg indoprofen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 300 mg indoprofen
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5 Gm lysine acetylsalicylate (ASA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.5 Gm lysine acetylsalicylate (ASA)
Number of subjects: 40
Study: 31889350

Group type: EXPERIMENTAL
Intervention: Education and counselling
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 105
Study: 31544383

Group type: EXPERIMENTAL
Intervention: Herbal cake‐separated moxibustion with new‐type moxibustion device combined with bladder function exercise
Number of subjects: 68

Group type: COMPARATOR
Intervention: Bladder function exercise
Number of subjects: 68
Study: 28304092

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 100
Study: 26406475

Group type: EXPERIMENTAL
Intervention: Nurse-led psychoeducational support program (3 sessions)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 155
Study: 24065377

Group type: EXPERIMENTAL
Intervention: AVNRT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AVRT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50

Group type: COMPARATOR
Intervention: AVNRT, AVRT, Control
Number of subjects: 50
Study: 21332573

Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) + Praziquantel (PZQ)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Albendazole (ABZ) alone
Number of subjects: 32
Study: 19583645

Group type: EXPERIMENTAL
Intervention: Efficacy-enhancing educational intervention (two 90-minute sessions between 33rd-35th weeks of pregnancy)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Efficacy-enhancing educational intervention
Number of subjects: 133
Study: 17149760

Group type: COMPARATOR
Intervention: 4 cycles of paclitaxel followed by 4 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) (n = 10)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: chemotherapy with simultaneous weekly trastuzumab for 24 weeks (n = 29)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: both treatment regimens
Number of subjects: 39
Study: 15233841

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: All-round, functional training
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Combination of resistance and all-round, functional training
Number of subjects: 173

Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 173
Study: 12130958

Group type: EXPERIMENTAL
Intervention: Gastric tube feeding
Number of subjects: 60

Group type: COMPARATOR
Intervention: Small-bowel tube feeding
Number of subjects: 60
Study: 10622504

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 47
Study: 7779309

Group type: EXPERIMENTAL
Intervention: Responder role
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inquirer role
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personal topics (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categorical topics (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit memory tests (cued recall and recognition)
Number of subjects: 0
Study: 2154047

Group type: EXPERIMENTAL
Intervention: Proton beam treatment
Number of subjects: 0
Study: 6781170

Group type: EXPERIMENTAL
Intervention: Rivanol-induced abortion
Number of subjects: 20
Study: 31726202

Group type: EXPERIMENTAL
Intervention: Subjective Allen's test
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Objective Princeps Pollicis Artery ultrasound
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Objective Barbeau test
Number of subjects: 54